BioNTech SE Sponsored ADR (BNTX)

BioNTech's stock price has fluctuated, with a share price of $85.68 as of March 27, 2026, a 5.91% decline from March 31, 2025. Key events include financial guidance for 2026 projecting a revenue decline, the departure of co-founders, reports linking COVID vaccines to heart conditions, Pfizer's intention to sell its stake, and reports linking COVID shots with child deaths. BioNTech reported second-quarter revenues of €260.8 million and reaffirmed its full-year revenue guidance. The company reported a net loss of €28.7 million for Q3 2025 and raised its full-year revenue guidance to €2.6 billion to €2.8 billion.

Demand seasonality for BioNTech is primarily driven by its COVID-19 vaccine, Comirnaty, with demand shifting to a seasonal endemic market. COVID-19 vaccine revenues are expected to be concentrated in the last three to four months of the year. The company is preparing for variant strain vaccine adaptation for the upcoming 2025/2026 vaccination season. As BioNTech pivots towards oncology, its future cancer therapeutics are not expected to exhibit the same seasonality.

BioNTech SE, headquartered in Mainz, Germany, is a biotechnology company specializing in immunotherapies and vaccines, particularly for cancer and infectious diseases. Its major product is the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, the first approved mRNA-based vaccine. BioNTech has a robust oncology pipeline, developing cancer therapeutics such as individualized immunotherapy, mRNA-based drugs, antibodies, and antibody-drug conjugates, leveraging advanced technology platforms.

BioNTech's global headquarters is in Mainz, Germany, with other sites in Germany, including Berlin, Halle (Saale), Idar-Oberstein, Marburg, and Munich. Internationally, it has offices and manufacturing sites in Europe, North America, Asia, Australia, and Africa. In December 2023, BioNTech inaugurated its first BioNTainer-based manufacturing site in Kigali, Rwanda, and announced a partnership to build a similar mRNA manufacturing plant in Melbourne, Australia. The Singapore facility serves as its regional headquarters and first mRNA manufacturing facility in Singapore. BioNTech's R&D infrastructure is strategically positioned across five continents.

BioNTech's brand reputation has been influenced by its transition from COVID-19 vaccines to oncology, discussions on vaccine safety, and leadership changes. The announcement of co-founders stepping down could raise questions about leadership continuity. Reports linking COVID vaccines to heart conditions and child deaths negatively affected vaccine manufacturers' reputation. BioNTech is actively working to reposition itself as a leader in oncology and mRNA innovation, aiming to become a multi-product oncology company by 2030.

BioNTech SE's ownership structure includes private equity firms (43%), institutional investors, and individual investors. The top two shareholders control 60% of the business, with insider ownership at 18%. Major institutional owners include AT Impf GmbH (43%), Medine GmbH (16.7%), Fmr Llc (Fidelity), Flossbach Von Storch Ag, Primecap Management Co/ca/, Dodge & Cox, T. Rowe Price Investment Management, Inc., Bnp Paribas Arbitrage, Sa, Temasek Holdings (Private) Ltd, Jane Street Group, Llc, Baillie Gifford & Co, and BlackRock, Inc. Ugur Sahin, the CEO, holds 18% of the shares.